Unidad de Investigación en Epidemiología Clínica, Instituto Mexicano del Seguro Social
Welcome,         Profile    Billing    Logout  
 2 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Escobedo, Jorge
NCT04591210: The COVID-RASi Trial (COVID-19)

Active, not recruiting
3
1155
Canada, RoW
Angiotensin converting enzyme inhibitor, Angiotensin II Receptor Blockers
Ottawa Heart Institute Research Corporation
COVID-19, Cardiovascular Diseases
12/24
12/25
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

Recruiting
2
400
Europe, Canada, RoW
semaglutide, Ozempic
Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto
Covid19, Myocardial Injury
03/22
03/22
FANTAZE, NCT04918927: Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Completed
2
120
RoW
Favipiravir, Nitazoxanide, Daxon, Nitazoxanide Placebo, Daxon Placebo
Coordinación de Investigación en Salud, Mexico, University College, London, Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV), Universidad Autonoma de Guadalajara, Siegfried Rhein S.A. de C.V., Strides Pharma Science Limited, Hakken Enterprise
Covid19
03/23
03/23
R-2018-785-100, NCT06278571: Effect of Education With Mobile App on Metabolic Control in Patients With Type 2 Diabetes

Recruiting
N/A
480
RoW
Educational intervention with App and web site education, Educational interventión with web site education, Control group with nutritional therapy
Coordinación de Investigación en Salud, Mexico
Female
04/25
12/25
Valenzuela, Julieta
NCT04591210: The COVID-RASi Trial (COVID-19)

Active, not recruiting
3
1155
Canada, RoW
Angiotensin converting enzyme inhibitor, Angiotensin II Receptor Blockers
Ottawa Heart Institute Research Corporation
COVID-19, Cardiovascular Diseases
12/24
12/25
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

Recruiting
2
400
Europe, Canada, RoW
semaglutide, Ozempic
Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto
Covid19, Myocardial Injury
03/22
03/22
Mateos, Eduardo
SEMPATICO, NCT04615871: Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19

Recruiting
2
400
Europe, Canada, RoW
semaglutide, Ozempic
Vladimír Džavík, Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto
Covid19, Myocardial Injury
03/22
03/22
NCT05124184: Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access

Completed
N/A
358
Europe
GORE® PROPATEN® Vascular Graft, GORE-TEX® Vascular Grafts
W.L.Gore & Associates
PAD - Peripheral Arterial Disease, AAA - Abdominal Aortic Aneurysm, End-Stage Renal Disease
07/24
07/24

Download Options